Daming capsule combined with SGLT2i confers protection against diabetes with myocardial ischemia/reperfusion injury induced ferroptosis via AMPK

Figure 6 Sodium-dependent glucose transporters 2 inhibitor combined with daming capsule inhibited ferroptosis in vitro and alleviated diabetes mellitus with ischemia-reperfusion. A: Flow chart of medicated medicine extracted; B: CCK-8 detects cell activity to determine the protective effect of drugs in vitro; C: Representative images of BODIPY 493/503 staining and statistical graph in treatment groups; D and E: Immunofluorescence was conducted to detect the expression of glutathione peroxidase 4 and 4-hydroxynonenal in treatment groups; F: Ion-specific fluorescent probe was used to detect the content of iron in treatment groups; G: Lipid peroxidation sensor BODIPY™ 581/591 C11 was employed to detect lipid reactive oxygen species levels in treatment groups; H: The changes of mitochondrial membrane potential in the treatment groups were analyzed by JC-1 fluorescent probe. Above results are presented as the mean ± SD. The comparison between more groups was conducted by one-way analysis of variance. ^aP < 0.05 vs the NULL group (diabetes mellitus + ischemia-reperfusion model); ^bP < 0.05 vs the high glucose + palmitic acid + hypoxia/reoxygenation group. HG: High glucose; PA: Palmitic acid; H/R: Hypoxia/reoxygenation; DMC: Daming capsule; SGLT2i: Sodium-dependent glucose transporters 2 inhibitor; GPX4: Glutathione peroxidase 4.